BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gounder PP, Bulkow LR, Snowball M, Negus S, Spradling PR, Simons BC, McMahon BJ. Nested case-control study: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance. Aliment Pharmacol Ther 2016;43:1197-207. [PMID: 27061300 DOI: 10.1111/apt.13621] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Alizadeh Zeinabad H, Ghourchian H, Falahati M, Fathipour M, Azizi M, Boutorabi SM. Ultrasensitive interdigitated capacitance immunosensor using gold nanoparticles. Nanotechnology 2018;29:265102. [PMID: 29629877 DOI: 10.1088/1361-6528/aabca3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Song A, Wang X, Lu J, Jin Y, Ma L, Hu Z, Zheng Y, Shen C, Chen X. Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta-analysis. J Viral Hepat 2021;28:601-12. [PMID: 33455067 DOI: 10.1111/jvh.13471] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Miao J, Gao P, Li Q, He K, Zhang L, Wang J, Huang L. Advances in Nanoparticle Drug Delivery Systems for Anti-Hepatitis B Virus Therapy: A Narrative Review. Int J Mol Sci 2021;22:11227. [PMID: 34681886 DOI: 10.3390/ijms222011227] [Reference Citation Analysis]
4 Ghany MG. Current treatment guidelines of chronic hepatitis B: The role of nucleos(t)ide analogues and peginterferon. Best Pract Res Clin Gastroenterol. 2017;31:299-309. [PMID: 28774412 DOI: 10.1016/j.bpg.2017.04.012] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
5 Li H, Sheng C, Wang S, Yang L, Liang Y, Huang Y, Liu H, Li P, Yang C, Yang X. Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9. Front Cell Infect Microbiol. 2017;7:91. [PMID: 28382278 DOI: 10.3389/fcimb.2017.00091] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 9.2] [Reference Citation Analysis]
6 Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: From discovery to regulatory approval. J Hepatol. 2017;67:847-861. [PMID: 28778687 DOI: 10.1016/j.jhep.2017.05.008] [Cited by in Crossref: 102] [Cited by in F6Publishing: 99] [Article Influence: 20.4] [Reference Citation Analysis]
7 Spradling PR, Xing J, Harris AM, Ly KN. Estimated prevalence and number of persons with isolated antibody to hepatitis B core antigen and associated occult hepatitis B, United States, 2001-2018. J Infect Dis 2021:jiab366. [PMID: 34252183 DOI: 10.1093/infdis/jiab366] [Reference Citation Analysis]
8 Tong MJ, Theodoro CF, Salvo RT. Late development of hepatocellular carcinoma after viral clearance in patients with chronic hepatitis C: A need for continual surveillance: Late onset of HCC after HCV clearance. Journal of Digestive Diseases 2018;19:411-20. [DOI: 10.1111/1751-2980.12615] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 Jiang JF, Sun J, Shi J, Liu X. Letter: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance. Aliment Pharmacol Ther 2017;45:1286-8. [PMID: 28370051 DOI: 10.1111/apt.13983] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
10 Vittal A, Sharma D, Hu A, Majeed NA, Terry N, Auh S, Ghany MG. Systematic review with meta-analysis: the impact of functional cure on clinical outcomes in patients with chronic hepatitis B. Aliment Pharmacol Ther 2022;55:8-25. [PMID: 34850415 DOI: 10.1111/apt.16659] [Reference Citation Analysis]
11 Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: From discovery to regulatory approval. Hepatology. 2017;66:1296-1313. [PMID: 28762522 DOI: 10.1002/hep.29323] [Cited by in Crossref: 129] [Cited by in F6Publishing: 130] [Article Influence: 25.8] [Reference Citation Analysis]
12 Chen YC, Liaw YF. Letter: hepatitis B surface seroclearance does reduce the risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2016;44:210-1. [PMID: 27296691 DOI: 10.1111/apt.13674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Lin CL, Kao JH. Review article: novel therapies for hepatitis B virus cure - advances and perspectives. Aliment Pharmacol Ther. 2016;44:213-222. [PMID: 27302653 DOI: 10.1111/apt.13694] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
14 Zhang X, Jia R, Xiang X, Gong W, Xiang B, Zhong J, Li L. Letter: older age and male gender increase the risk of hepatocellular carcinoma after hepatitis B surface antigen (HBsAg) seroclearance. Aliment Pharmacol Ther 2017;46:906-8. [DOI: 10.1111/apt.14272] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
15 Gounder PP, Bulkow LR, McMahon BJ. Letter: hepatitis B surface seroclearance does reduce the risk of hepatocellular carcinoma - authors' reply. Aliment Pharmacol Ther 2016;44:650-1. [PMID: 27511139 DOI: 10.1111/apt.13730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
16 Kuang XJ, Jia RR, Huo RR, Yu JJ, Wang JJ, Xiang BD, Li LQ, Peng Z, Zhong JH. Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J Viral Hepat 2018;25:1026-37. [PMID: 29624821 DOI: 10.1111/jvh.12905] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]